CSL

EU Legislative Interests

• Critical Medicines Act • Public Procurement Directive • Biotech Act • Life Sciences Strategy • Pharmaceutical Strategy (including OMP legislation) • SoHO legislation • Preparedness and Medical Countermeasures • Stockpiling Strategy • Trade Policy • Open Strategic Autonomy • EU Rare Disease Action Plan • Cross-border healthcare • European Health Data Space • Health Technology Assessment • EU competitiveness • Non-communicable diseases policies • Economic security

Communication Activities

Activities conducted through CSL Behring: • Meetings with policy makers in the EU institutions and participation to EU consultations • Parliament Magazine Article: Critical Medicines Act: Ensuring Steady Supply of Plasma-Derived Therapies (October 2025) • Parliament Magazine Article: The EU's Role in Advancing Access to Gene Therapy for patients (May 2025) • European Parliament Roundtable: "A Vibrant Europe for Critical Medicines and Biotech: Spotlight on Plasma-Derived Therapies" (October 2025) • European Health Summit: Critical Medicines Act: A Strategic Driver of Resilience and Global Competitiveness in Europe's Pharma and Biotech Sectors (December 2025) • Parliament Magazine Article: Policy recommendations on better diagnosis and care for HAE and rare disease patients in Europe (December 2024) • Policy debate on hereditary angioedema hosted by MEP Andriukaitis and MEP Bosse in VoxBox studio, European Parliament (December 2024) • Feature in The Parliament Magazine on improving HAE diagnosis and care with input from members of the European Parliament (November 2024) Activities conducted through CSL Vifor: • Publication of Blood and Beyond's policy recommendations "5-Point Plan for Better Health in Europe" (April 2025) • Joint statement on implementing Patient Blood Management in Europe, supported by MEPs (autumn 2024-November 2025) • Policy debate on blood health, hosted by MEPs Sokol and Hadjipantela, European Parliament (April 2025) • Media article 'Blood Health Matters: EU Policy Action on PBM Implementation" in The Parliament (April-November 2025) • Ongoing meetings with policymakers to discuss how to improve blood health in Europe and EU action

Interests Represented

Promotes their own interests or the collective interests of their members

Member Of

• EFPIA - The European Federation of Pharmaceutical Industries and Associations • EUCOPE - The European Confederation of Pharmaceutical Entrepreneurs • EuropaBio - The European Association for Bioindustries • ARM - The Alliance for Regenerative Medicine • Parliament Magazine • European Business Summits • European Policy Centre • Friends of Europe • EKHA - European Kidney Health Alliance • Blood & Beyond • Transform Alliance

Organisation Members

N/A

Additional Information

CSL Behring and CSL Vifor are integrating under a new entity, legal group entity, CSL. Therefore, we have updated the transparency registry entry of CSL Behring (030031840349 92) to merge it with Vifor (283361852096 45). Therefore, the previous Vifor entry (283361852096 45) has now been deleted and integrated under the new CSL entry (030031840349 92). This means that we have reported data for the closed and current financial year for both Vifor and Behring under the new CSL entry. Specifically: o Activities covered by the register provided by Acumen for CSL Vifor fall under the bracket €10,000 - €24,999 o Activities covered by the register provided by DGA Group Europe SA for CSL Vifor fall under the bracket €25,000-49,000 o Activities covered by the register provided by DGA Group Europe SA for CSL Behring fall under the bracket €50,000 - €99,999 o Activities covered by the register provided by APCO for CSL Behring fall under the bracket €50,000 - €99,999 Please note that any potential discrepancy compared to what consultancies declare is due to different financial years. The estimate of annual costs includes consultancy fees (as declared above), relevant percentage of trade associations' work, percentage of salaries and office expenses.